Faeth Therapeutics reported a net loss of $20.4 million
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001193125-26-444376
- Net loss: $20.4 million for the three months ended Sep 30, 2026
- Diluted EPS: -$0.79 for the three months ended Sep 30, 2026
- Cash and equivalents: $14.18 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
The reading, claim by claim
From the filing's financial data, not stated in its text
From this 10-Q's financial data (XBRL) for the quarter ended September 30, 2026
- For the quarter ended September 30, 2026, Faeth Therapeutics, Inc. reported: Net income -$20.4 million.
From the filing
Item 1. Condensed Consolidated Financial Sta tements (Unaudited)
Item 1. Condensed Consolidated Financial Sta tements (Unaudited)
FAETH THERAPEUTICS, INC.
CONDENSED CONSOLIDA TED BALANCE SHEETS
(Unaudited)
(In thousands, except share and per share data)
September 30,
2026
December 31,
2025
Assets
Current assets:
Cash and cash equivalents
$
14,180
$
8,668
Marketable securities
160,615
12,516
Prepaid expenses
1,412
231
Other current assets
1,634
92
Total current assets
177,841
21,507
Right-of-use assets - operating leases, net
126
1,294
Right-of-use assets - financing leases, net
—
1
Property and equipment, net
1
82
Other non-current assets
981
18
Total assets
$
178,949
$
22,902
Liabilities, redeemable convertible preferred stock and stockholders' equity
Current liabilities:
Accounts payable and accrued expenses
$
8,630
$
1,481
Compensation and employee benefits liabilities
2,257
1,320
Operating lease liabilities, current
145
1,370
Financing lease liabilities, current
—
80
Total current liabilities
11,032
4,251
Operating lease liabilities, non-current
—
59
Other non-current liabilities
53
—
Total liabilities
11,085
4,310
Commitments and contingencies (Note 7)
Series B redeemable convertible preferred stock, $ 0.0001 par value; 502 and zero shares authorized as of September 30, 2026 and December 31, 2025, respectively; 502 and zero shares issued and outstanding as of September 30, 2026, and December 31, 2025, respectively; liquidation value of $ 0 as of September 30, 2026
6,767
—
Stockholders' equity:
Preferred stock, $ 0.0001 par value and 10,000,000 shares authorized as of September 30, 2026 and December 31, 2025; zero shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively
—
—
Common stock, $ 0.0001 par value; 300,000,000 shares authorized as of September 30, 2026 and 12,500,000 shares authorized as of December 31, 2025; 25,842,318 and 1,261,685 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively
3
—
Additional paid-in capital
651,025
301,728
Accumulated de
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Zeo ScientifiX ZEOX public float $7M, Apr 30, 2025, over 18 months old
- Sunshine Biopharma SBFM public float $7M, Jun 30, 2025
- Neuphoria Therapeutics NEUP public float $7M, Dec 31, 2025
- CV Sciences CVSI public float $7M, Jun 30, 2025
- Minerva Neurosciences NERV public float $7M, Jun 30, 2025